Capricor Therapeutics (NASDAQ:CAPR) Shares Up 7.4% – Here’s Why

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s stock price was up 7.4% on Thursday . The stock traded as high as $20.29 and last traded at $20.3040. 644,411 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 1,291,429 shares. The stock had previously closed at $18.91.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CAPR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Monday, June 15th. Roth Capital reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Capricor Therapeutics in a research report on Friday, May 15th. LADENBURG THALM/SH SH raised Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $53.67.

Capricor Therapeutics Stock Performance

The stock has a 50-day moving average price of $25.67 and a two-hundred day moving average price of $27.58. The stock has a market capitalization of $1.16 billion, a PE ratio of -8.71 and a beta of 0.42.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, equities analysts predict that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Insider Buying and Selling at Capricor Therapeutics

In other news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at $260,669.10. This represents a 75.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 50,000 shares of company stock valued at $1,551,658 in the last three months. Corporate insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. increased its stake in Capricor Therapeutics by 122.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock worth $37,000 after buying an additional 2,786 shares in the last quarter. ACT Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $43,000. KBC Group NV bought a new position in shares of Capricor Therapeutics in the first quarter worth about $44,000. Tower Research Capital LLC TRC boosted its stake in shares of Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock worth $67,000 after acquiring an additional 4,976 shares during the period. Finally, Regal Investment Advisors LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter worth about $92,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.